![College of Pharmacy Faculty Research and Publications](../../assets/md5images/15f9f0b18dd4c040815af3e6c4efc5f1.jpg)
College of Pharmacy Faculty Research and Publications
New Drug: Tirzepatide (Mounjaro™)
Document Type
Article
Publication Title
The Senior Care Pharmacist
Publication Date
2-1-2023
Volume
38
Issue
2
First Page
50
Last Page
62
Abstract
Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and is a chronic and progressive illness. Millions of Americans have T2DM and many patients do not achieve the recommended blood glucose levels. Glucagon-like peptide 1 (GLP-1) based therapy is an established treatment for the management of T2DM and is recommended early in the treatment algorithm. GLP-1 therapy is associated with better glycemic control, weight reduction, and favorable cardiovascular outcomes. Tirzepatide (Mounjaro™) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 receptor agonist. Evidence from five SURPASS clinical trials has demonstrated that tirzepatide has potent glucose lowering and weight loss with adverse effects comparable to GLP-1 receptor agonists. This paper gives an overview of tirzepatide and SURPASS clinical trials.
Copyright held by
American Society of Consultant Pharmacists
Recommended Citation
Gettman, L. (2023). New Drug: Tirzepatide (Mounjaro™). The Senior Care Pharmacist, 38 (2), 50-62. http://dx.doi.org/https://doi.org/10.4140/TCP.n.2023.50